Please assess the completion status of the following clinical trial:

Trial Title: ExploR® Modular Radial Head Data Collection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~The inclusion criteria will be the same as the indications stated in the FDA cleared (510(k) K040611) and (510(k) K051385) labeling for the device.~1. Replacement of the radial head for degenerative or post-traumatic disabilities presenting pain, crepitation, and decreased motion at the radio-humeral and/or proximal radio-ulnar joint with:~   1. Joint destruction and/or subluxation visible on x-ray~  2. Resistance to conservative treatment~2. Primary replacement after fracture of the radial head~3. Symptomatic sequelae after radial head resection~4. Revision following failed radial head arthroplasty~The device is intended for single use with or without bone cement.~Modular Radial Head replacement prostheses have received FDA clearance for cemented and non-cemented application.~Patient selection factors to be considered include: 1) need to obtain pain relief and improve function, 2) ability and willingness of the patient to follow instructions, including control of weight and activity levels, 3) a good nutritional state of the patient, and 4) the patient must have reached full skeletal maturity.~Exclusion Criteria:~The exclusion criteria will be the same as the contraindications stated in the FDA cleared labeling (510(k) K040611) and (510(k) K051385) for the device. These contraindications include:~Absolute contraindications:~1. Infection~2. Sepsis~3. Osteomyelitis~Relative contraindications:~1. Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions~2. Osteoporosis~3. Metabolic disorders which may impair bone function~4. Osteomalacia~5. Distant foci of infections which may spread to the implant site~6. Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).